Get started
Cytosorbents CorporationCytosorbents CorporationCytosorbents Corporation

Cytosorbents Corporation

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

CTSO trade ideas

CTSO Sucker wave is nextHello, What is CTSO? Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. News My Thoughts For You I see a bearish divergence on the daily TF from wave 3 to 5 and suspect that A wave is nearly completed. The next move is the suckers B wave which will be a great short for the sharp drop down for C wave. Wait for B wave to complete by watching the 4hr TF, look for signs of a reversal for your entry. Good Luck, Cheers! Be sure to comment, follow, like, and check out my profile for more trade ideas!
NASDAQ:CTSOShort
by keifer
1
CTSO: Strong BuySummary Target $30, Stop $5. (Analyst price-targets around $14-$17). COVID-19 put spotlight on their flagship product Cytosorb, as it gained emergency FDA approval for treatment of severe COVID-19 patients. As further approvals for removal of ticagrelor and rivaroxaban have followed, Cytosorb can potentially become the "standard of care" alongside blood thinners. Headwinds have translated to record quarterly revenue, sales order backlog, operations running at full capacity. Not a COVID play, but this crisis has definitely been a tailwind for the company. Even after COVID goes away, those tailwinds and physician adoption will persist to create high growth Background: In April, Cytosorb received Emergency Use Authorization (EUA) from FDA for critical COVID-19 patients. This was followed up by a Breakthrough Designation for removal of ticagrelor in cardiac surgery patients. Later, it also received EU approval for removal of rivaroxaban during cardio-thoracic surgery. Q1 was already turning out to be a strong quarter with a 80% yoy growth in product sales, and the ongoing COVID-19 pandemic has brought the company's flagship product to the forefront of attention within the medical community to treat cytokine storms and deadly inflammation in critically ill COVID-19. CTSO ended the quarter with their first-ever sales order backlog of $2.7 million (c.30% of Q2 expected revenue), and thus have ramped production to full capacity to fulfill that. As physician awareness increases, Cytosorb could see a huge tail-wind in growth due to COVID-19 Financial highlights: Even prior to 2020, the company had been seeing steady revenue growth rates of ~40% p.a. from 2016-2019. Q1 total sales came in at $8.7million (~80% yoy growth), which represents a roughly ~12x price to sales ratio. Product gross margins of ~75% are healthy, and could potentially see a bump from economies of scale as product adoption increases. As mentioned above, company enters Q2 with a $2.7M backlog and have raised production to "near full capacity". Production capacity is $80M (i.e. $20M per quarter). Working capital look solid. Company ended Q1 with $26.5M in cash, and have refinanced a $15M loan facility. (vs. net loss of $3.5M in Q1; gross profit of $6.3M) Investment thesis: 1) Conservative case: Revenue 2020E: ~$50M (conservatively, details below)Gross profit: $37.5M (75% margin)Assuming a 20x P/gross profit (where it's approx trading), that equates to $750M market cap, so ~85% potential 2) Aggressive case: Revenue 2020E: ~$65MGross profit: $50M Assuming a 25x P/gross profit (multiples expansion due to higher growth, that equates to $1.2bn company, hence price-target of ~$30 Expect the company to surpass the 2018 high of 14.8 in Q2 and to continue growing Underlying assumptions for revenue estimates: Q2 should see a bump in revenues due to backlog, increased COVID-19 patients, and following new approvals for cardiac patients. Expect the company to see a decline in demand from non COVID patients, but don't expect it to be much given this is a therapy for critically ill patients (stroke, sepsis, trauma, ARDS shock and ICU admissions) rather than for elective surgery patients. Q1: $9MQ2E: $15M conservatively ($12M new demand + $2.7M backlog) (Arrived via three routes:a: they've been running at close to full capacity of $20Mb: Q1 demand was already $11M if you include backlog (assumed a 10% bump)c: Q1 had $1.5M-$1.7M demand from COVID, which hit in March. Accounting for a full quarter and not adjusting for rise in cases, that equates to additional $3-$3.5M demand, but applying a haircut of ) Q3E and Q4E: $13M conservatively (though I would argue this would be closer to $20M as influenza season begins again and physician awareness increases) For aggressive case, I believe we're looking at Q2E: $20M ($17M new demand + $2.7M backlog) - given Q1 earnings call statement of operating at close to full capacity, and increasing COVID-19 cases that have transpired Q3E and Q4E: $18M In the aggressive case, we will likely see the company looking to add production capacity in Q3/Q4 onwards, and revenue maybe more than that. Disclosure: I am/we are long CTSO.
NASDAQ:CTSOLong
by trueblue_08
$CTSO Added to COVID-19 Treatment List MONMOUTH JUNCTION, N.J., March 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provided an update from its Chief Executive Officer, Dr. Phillip Chan, MD, PhD. CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation) CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation) More "We are witnessing an acceleration of the COVID-19 pandemic as the total number of infected patients has surpassed 420,000 in 197 countries around the world," stated Dr. Chan. "Italy has been the hardest hit, with the highest mortality of any major country. Physicians there describe the lung injury caused by COVID-19 pneumonia as the worst they have seen from any respiratory viral infection in recent history, leading to an atypically long 2-4 week dependence on mechanical ventilation, if critically-ill patients can survive that long. These comments mirror the experience reported in China and help to explain why many intensive care units (ICUs) have been overwhelmed with patients, and how a lack of resources such as mechanical ventilators and beds have led to a crisis in care." "Meanwhile, the United States is experiencing a dramatic surge of new cases this week, as New York and New York City have emerged as the epicenter of infection, accounting for approximately half, and a quarter of all cases, respectively, in the country. Already, hospitals in New York City are reporting a spike in hospitalized patients, as well as those with severe disease in the intensive care unit (ICU) requiring mechanical ventilation with rapidly progressive respiratory failure. It is expected to only worsen over the next several weeks. Meanwhile, this is a global phenomenon, with cases in Italy, Germany, Spain, and France still rising rapidly." "As the pandemic worsens, the use of CytoSorb in patients infected with COVID-19 has now begun. CytoSorb has now been used in more than 70 COVID-19 patients to help treat cytokine storm and life-threatening complications such as acute respiratory distress syndrome (ARDS) and shock in Italy, China, Germany, and France. Due to the crisis, the ability to obtain patient level data has been very limited. However, based upon initial, preliminary verbal reports from physicians treating these complications, CytoSorb use has generally been associated with a marked reduction in cytokine storm and inflammation, improved lung function, weaning from mechanical ventilation, and a reversal of shock. Certainly not all treatments have been successful in this critically-ill patient population that verges on death, particularly when used too late. However, based on the initial positive results of the therapy, CytoSorb is now specifically recommended in the Italy Brescia Renal COVID Task Force Guidelines to treat patients with severe COVID-19 infection and Stage 3 renal failure on continuous renal replacement therapy (CRRT), published last week on the Italian Society of Nephrology website. As we mentioned previously, this follows the recommendation to treat cytokine storm with blood purification in COVID-19 infection by the National Health Commission in China in their treatment guidelines, entitled "Diagnosis and Treatment of New Coronavirus Pneumonia (7th Version)." In addition, based upon prior experience with CytoSorb in the treatment of critical illnesses, the soon to be posted National Treatment Guidelines from Panama for Adult COVID-19 patients now recommends the use of CytoSorb if patients have either refractory shock, or have severe or refractory respiratory failure requiring either high ventilator support or extracorporeal membrane oxygenation (ECMO - a machine that can oxygenate blood outside the body if the lungs become non-functional). CytoSorb has been used in thousands of ECMO treatments to date in non-COVID-19 patients around the world."
NASDAQ:CTSOLong
by DEXWireNews
CTSO Pre Earnings STOCK SETUPCTSO is set to report earnings early next week, given that this was a requested chart, I have not had time to dig in to the company's fundamental financials and create a good estimate of what to expect from its earnings. GIVEN THE TECHNICAL ANALYSIS ALONE: WE are currently hovering a buy zone, and have broken in to it once. At its current level, we are ready to buy PROTECTING at the red horizontal. This is the bottom of a weekly range and, with a bad earnings report, the place where our stock will find its first resistance. HOWEVER, from our buy level we are currently at I have set 2 key price target levels to reach, of course which you are shooting for is up to you, but both targets would be where I take my profits as a trader. Remember, earnings early next week that can explode a chart in front of you eyes- so be careful.
NASDAQ:CTSOLong
by samblum_